Serum Adiponectin Concentration, Activity and Isoforms in Chinese Population and Its Correlation to Cardiovascular and Cerebrovascular Diseases
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 30,000
- Locations
- 1
- Primary Endpoint
- Number of Participants with major adverse events
Study Overview
Brief Summary
Adiponectin (Ad) is an abundant protein in human body, and reports have shown that it act as a novel risk factor for brain and heart ischemia injury. This 5 years follow-up study will focus on serum adiponectin concentration, activity and isoforms in Chinese population and its correlation to these diseases.
Detailed Description
Adiponectin (Ad) is an abundant protein hormone regulatory of numerous metabolic processes, anti-inflammatory, vascular protective, and anti-ischemic properties. Since its 1995 discovery, Ad has garnered considerable attention for its role in diabetic and cardiovascular pathology. Clinical observations have demonstrated the association of hypoadiponectinemia in patients with obesity, cardiovascular disease, and insulin resistance. There is growing evidence supporting Ad can act as a novel risk factor for cardiovascular and cerebrovascular injury. This 5 years follow-up study will focus on serum adiponectin concentration, activity and isoforms in Chinese population and its correlation to cardiovascular and cerebrovascular diseases.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to 85 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •available for 5 years of follow-up study
Exclusion Criteria
- •Death caused other than cardiovascular and cerebralvascular diseases till the study ends
- •Floating Population
- •Pregnancy, lactation, or child bearing women
- •Active hepatic disease or hepatic dysfunction, or AST/ALT > 1.5UNL
- •Severe renal dysfunction(Scr > 3 mg/dl or 264μmol/L)
- •Patients with any condition which, in the investigator's judgment, might increase the risk to the subject for any adverse event or abnormal laboratory finding
Outcomes
Primary Outcomes
Number of Participants with major adverse events
Time Frame: 5 years
Major adverse events included but were not limited to death during the study caused by cardiovascular events or cerebrovascular events.
Secondary Outcomes
- serum adiponectin concentration, activity and isoforms(5 years)
- blood routine, glucose and lipid profile; ECG;(5 years)